Stockscreener 앱 받기
4.37
0.46%
-0.02
전일 마감가:
$4.39
열려 있는:
$4.35
하루 거래량:
13,428
Relative Volume:
0.04
시가총액:
$6.49M
수익:
$5.18M
순이익/손실:
$-7.79M
주가수익비율:
-1.8517
EPS:
-2.36
순현금흐름:
$-4.99M
1주 성능:
-4.17%
1개월 성능:
-17.55%
6개월 성능:
-15.70%
1년 성능:
-71.99%
1일 변동 폭
$4.31
$4.45
1주일 범위
$4.26
$4.61
52주 변동 폭
$3.54
$17.40
Evoke Pharma Inc Stock (EVOK) Company Profile
명칭
Evoke Pharma Inc
전화
858-345-1494
주소
420 STEVENS AVENUE, SOLANA BEACH, CA
EVOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.37 | 6.49M | 5.18M | -7.79M | -4.99M | -2.36 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | 재개 | FBR & Co. | Buy |
| 2017-03-16 | 재확인 | Rodman & Renshaw | Buy |
| 2017-01-30 | 업그레이드 | Laidlaw | Neutral → Buy |
| 2017-01-05 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | 재확인 | Rodman & Renshaw | Neutral |
| 2016-07-19 | 재확인 | FBR Capital | Outperform |
| 2016-07-19 | 다운그레이드 | Noble Financial | Buy → Hold |
| 2016-07-18 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | 개시 | Northland Capital | Outperform |
| 2016-03-14 | 재확인 | Ascendiant Capital Markets | Buy |
| 2016-02-17 | 재개 | FBR Capital | Outperform |
| 2014-12-03 | 재확인 | MLV & Co | Buy |
| 2014-11-07 | 개시 | MLV & Co | Buy |
| 2014-04-22 | 개시 | Laidlaw | Buy |
| 2013-11-19 | 개시 | Aegis Capital | Buy |
모두보기
Evoke Pharma Inc 주식(EVOK)의 최신 뉴스
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire
Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve
By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK
(EVOK) Trading Advice - Stock Traders Daily
BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times
Evoke Pharma Reports Q3 2024 Financial Results - TipRanks
Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Is Abbott Laboratories (ABT) the Best Pharma Stock to Buy Right Now? - Yahoo Canada Finance
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit - Yahoo Finance
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Global Digestive Health Market Size, Share And Growth Analysis For 2024-2033 - EIN News
Canopy Growth Corporation (CGC) Stock Price, News, Quote & History - Yahoo Finance
Evoke Pharma (FRA:EV0) Enterprise Value : €1.02 Mil (As of Nov. 01, 2024) - GuruFocus.com
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Become Profitable? - Simply Wall St
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Five things for pharma marketers to know for Tuesday morning - MM+M Online
S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings - MSN
Evoke Pharma holds Buy rating with $18 target from Laidlaw - Investing.com
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024 - MSN
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis - Yahoo Finance
What made Evoke Pharma stock more than double on Monday? - Invezz
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher - Benzinga
Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users - MarketWatch
Evoke stock rockets 90% on study of Gimoti in GLP-1 users (NASDAQ:EVOK) - Seeking Alpha
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Evoke Pharma Stock Is Soaring Monday: What's Going On? - Benzinga
Evoke Pharma reports significant benefits of GIMOTI in DGP study - Investing.com India
Evoke Pharma & EVERSANA Announce Statistically Significant - GlobeNewswire
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - StockTitan
Evoke Pharma Inc (EVOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
1.03%
자본화:
|
볼륨(24시간):